Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals Inc (NQ: RYTM )

39.35 -4.53 (-10.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday
Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th. 
Via Benzinga
Rhythm Pharma's Setmelanotide Shows Encouraging Action In Hypothalamic Obesity Study
Via Benzinga
5 Analysts Have This to Say About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals (NASDAQ:RYTM) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Rhythm Pharma Secures Non-Dilutive Financing Of $100M To Use Of This...
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
This Healthcare Stock is Down By More Than 50%: Here's 25 Stocks Moving Premarket
Gainers 
Via Benzinga
Crude Oil Prices Fall Sharply; Greenwich LifeSciences Shares Spike Higher
U.S. stocks traded mixed toward the end of trading after recording losses in the previous session. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Rhythm Shares Climb Following Positive Interim Results From Mid-Stage Obesity Study
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced positive interim results from a Phase 2 clinical trial evaluating setmelanotide for the treatment of severe obesity and hyperphagia in people living with... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. 
Via Benzinga
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
U.S. Markets Open Higher; Dow Rises Around 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Friday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're entering the final day of trading for the week with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
21 Stocks Moving in Friday's Pre-Market Session
Gainers Athersys, Inc. (NASDAQ: ATHX) rose 48.5% to $0.4755 in pre-market trading after dropping more than 12% on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 34.4% to $2.81 during Thursday's after-market session. The market value of their outstanding shares is at $29.0 million. 
Via Benzinga
Rhythm Pharmaceuticals' Shares Dive Following FDA's Verdict On IMCIVREE Drug
The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ (NASDAQ: RYTM) supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R)... 
Via Benzinga
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
5 Biotech Stocks To Watch During The Week Of June 13
Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a... 
Via Benzinga
30 Stocks Moving in Monday's Pre-Market Session
Gainers G Medical Innovations Holdings Ltd (NASDAQ: GMVD) rose 53.6% to $0.5301 in pre-market trading after dropping more than 28% on Friday. 
Via Benzinga
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
These biotech stocks face some key make-or-break events in June that could have big implication for their futures. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.